pam3csk4

Pam3CSK4 is a synthetic triacylated lipopeptide (LP) that mimics the acylated amino terminus of bacterial LPs.

Pam3CSK4 TFA (Pam3Cys-Ser-(Lys)4 TFA) is a Toll-like receptor 1/2 agonist with EC50 of 0.47 ng/mL for human TLR1/2.

Pam3CSK4-Biotin is a biotinylated derivative of Pam3CSK4, functioning as a Toll-like receptor 1/2 (TLR1/2) agonist.

Pam3CSK4-Biotin (Pam3Cys-Ser-(Lys)4-Biotin) TFA is the biotinylated version of Pam3CSK4. It acts as an agonist for Toll-like receptor 1/2 (TLR1/2).

CU-CPT22 is the first probe for the complex between toll-like receptors TLR1 and TLR2. CU-CPT22 binds at the interface of TLR1 and TLR2 (IC50 = 0.58 μM). It competes with the synthetic triacylated lipoprotein (Pam3CSK4) binding to TLR1/2 (Ki: 0.41 μM).

MMG-11 inhibits both TLR2/1 and TLR2/6 signaling (IC50s: 1.7 μM for Pam3CSK4-induced hTLR2/1 and 5.7 μM for Pam2CSK4-induced hTLR2/6 responses). MMG-11 is an effective and selective human TLR2 antagonist with low cytotoxicity.

MMG-11 quarterhydrate is a potent and selective antagonist of human TLR2, inhibiting both TLR2/1 and TLR2/6 signaling with low cytotoxicity. The IC50 values for Pam3CSK4-induced hTLR2/1 and Pam2CSK4-induced hTLR2/6 responses are 1.7 μM and 5.7 μM, respectively [1].

NCI 126224 is a Toll-like receptor 4 (TLR4) antagonist that selectively inhibits nitric oxide production induced by the TLR4 agonist LPS in RAW 264.7 macrophages (IC50 = 0.31 µM), while exhibiting weaker effects against the TLR7/8 agonist R-848, TLR1/2 agonist Pam3CSK4, and TLR3 agonist poly(I:C). NCI 126224 also inhibits FSL-1-induced NO production at 0.6 µM and suppresses LPS-induced NF-κB activity in BV-2 glial cells, while reducing IL-1β and TNF-α levels in RAW 264.7 cells (IC50s of 5.92 and 1.54 µM, respectively). 0.42, and 1.54 µM, respectively), demonstrating its significant value in studies of inflammatory and innate immune signaling pathways.